Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16167 ↗At a glance
Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2025. Written by Carel W le Roux and 6 co-authors. Institution: St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland. Major MEDLINE topics: Body Mass Index, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Hypoglycemic Agents. Cited 11 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Boehringer Ingelheim.
Abstract (original language)
Aim
To explore the effects of sex and baseline body mass index (BMI) on the efficacy and safety of survodutide in people with a BMI ≥27 kg/m 2 . Materials and Methods Totally 387 people (aged 18–75 years, BMI ≥27 kg/m 2 , without diabetes) were randomized 1:1:1:1:1 to once‐weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20‐week dose escalation; 26‐week dose maintenance). Participants were categorized according to sex and baseline BMI. Data were analysed descriptively for the full analysis set (FAS), according to dose assigned at randomization (planned treatment) using on‐treatment data or all data censored for COVID‐19‐related treatment discontinuations. ( ClinicalTrials.gov number: NCT04667377).
Results
After 46 weeks of survodutide treatment, females had greater reductions in bodyweight and waist circumference than males. Participants with a lower baseline BMI had greater proportional reductions in bodyweight than those with a higher baseline BMI; the trend was reversed for reductions in waist circumference. Rates of adverse events (AEs) were comparable between subgroups for sex and baseline BMI. Nausea was the most frequently reported gastrointestinal AE in all subgroups.
Conclusions
In people with a BMI ≥27 kg/m 2 , survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI, and was tolerated at all doses tested.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland.
- Private Practice, Toronto, Ontario, Canada.
- Diabetes and Endocrinology Consultants, Morehead City, North Carolina, USA.
- Boehringer Ingelheim International GmbH, Ingelheim, Germany.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
- Boehringer Ingelheim International GmbH, Biberach, Germany.
ORCID profiles: Carel W le Roux, Anita M Hennige
Funding
- Boehringer Ingelheim
Cite
APA
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., Hussain, S. A., & Hennige, A. M. (2025). Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16167
Vancouver
le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hussain SA, et al. Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16167
BibTeX
@article{leRoux2025,
author = {le Roux, Carel W and Steen, Oren and Lucas, Kathryn J and Startseva, Elena and Unseld, Anna and Hussain, Samina Ajaz and Hennige, Anita M},
title = {Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16167}
}
EUVIMED